PDCD1 and non-small cell lung carcinoma: Herein, we report the rationale and study protocol of this randomized phased II trial (the InTRist study), to determine the therapeutic effect of induction and consolidation anti-PD-1 toripalimab in combination with radical radiotherapy for bulky unresectable LA-NSCLC.